Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'Mock' Recalls Suggested, But US FDA Isn't Joking About Recalling Products

Executive Summary

FDA's suggestions in voluntary recalls draft guidance largely track with advice attorneys long have offered consumer health product firms. Instead, on top of November guidance on mandatory recall authority and February guidance on recall public notifications, FDA is making clear its expectations for firms' preparedness for recalls and their responses when faced with removing products from store shelves.

You may also be interested in...



US FDA's Expectations And Firms’ Responsibilities Clarified In Voluntary Recalls Final Guidance

Final guidance describes in greater detail than draft published in 2019 the agency’s expectations for marketers and other businesses’ responses when they need to recall FDA-regulated products.

Support To Grant US FDA Authority To Order Recalls Of All Drugs Grows With Bill Introduced In Senate

Sen. Gary Peters says FDA should have the authority because relying on drug marketers to voluntarily recall products the agency has deemed unsafe isn’t sufficient to protect public health. He notes that manufacturers of OTC hand sanitizers imported from Mexico and found to contain methanol haven’t cooperated with the FDA on recalling the products.

Expanding US FDA Mandatory Recall Authority To All Drugs Gets House Appropriators’ Approval

Appropriators’ FDA FY 2021 budget includes amendment to expand its mandatory recall authority introduced by chairman of subcommittee with oversight of agency’s budget, Rep. Sanford Bishop. He said the agency should be able to force drug product recalls as it already can for vaccines, medical devices and products containing ingredients also scheduled as controlled substances.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel